This site is intended for healthcare professionals
DNA AI generated image
  • Home
  • /
  • Medical Education
  • /
  • Molecular biomarker testing for prostate cancer
  • /
  • Podcast 1: Reviewing guidelines on genetic and gen...

Podcast series: Molecular biomarker testing for prostate cancer

These podcasts have been developed and funded by AstraZeneca and are intended for healthcare professionals only.
Last updated: 12th Apr 2024
Published:12th Apr 2024

Listen to this podcast series on metastatic castration-resistant prostate cancer (mCRPC), featuring insights from leading experts on the current molecular testing landscape and perspectives on the predictive value of HRR/BRCA mutation (BRCAm) status.

Podcast 1: Reviewing guidelines on genetic and genomic testing in mCRPC

Dr Rana McKay (USA), Dr Elena Castro (Spain) and Professor Yao Zhu (China) share their perspectives on patient selection for genetic testing, which genes should be tested and their experiences with tissue and ctDNA testing.

Meet the experts

Dr Rana McKay.png

Dr Rana McKay

Dr Rana McKay is a medical oncologist specialising in genitourinary tumours. Dr McKay serves as an associate professor of medicine and urology at the University of California, USA, associate director of translational sciences, interim associate director of clinical sciences, and co-lead of the genitourinary oncology program, where she conducts research focused on developing novel therapies for people with advanced prostate and kidney cancers.

Disclosures: Consultant/advisory board fees from Ambrx, AstraZeneca, Aveo Oncology, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, Seagen, Sorrento Therapeutics, Telix, and Tempus. Institutional research funding from ArteraAI, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Oncternal Therapeutics, and Tempus.

Dr Elena Castro.png

Dr Elena Castro

Dr Elena Castro is a medical oncologist specialising in prostate cancer. She conducts research at the Spanish National Cancer Research Center in Madrid, Spain. Her work primarily involves the molecular characterisation of prostate cancer and development of new treatment strategies.

Disclosures: Financial support from Astellas, AstraZeneca, Bayer, Daiichi Sankyo, Janssen, Lilly, Medscape, Merck, MSD, Novartis, Pfizer, Sandoz, and Telix.

Professor Yao Zhu.png

Professor Yao Zhu

Professor Yao Zhu is a consultant urologist specialising in urologic cancers. He is a professor of oncology at Shanghai Medical College, China. His extensive research in urologic cancers, particularly prostate and bladder cancer, has led to significant contributions to the field.

Disclosures: Financial support from AstraZeneca, Bayer, and Janssen.


Developed by EPG Health for Medthority with content provided by AstraZeneca in order to help provide healthcare professionals with access to the highest quality medical and scientific information, education and associated relevant content [Z4-61762, February 2024 | Recording Z4-61705, February 2024].